-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
1FW2:F:F- (EUR)
COMMON STOCK | Biotechnology |
Last Closing
USD 1.4258Change
+0.03 (+2.12)%Market Cap
USD 6.04BVolume
208.00Verdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 1.4258Change
+0.03 (+2.12)%Market Cap
USD 6.04BVolume
208.00Verdict
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
NOVA:F | Novo Nordisk A/S |
N/A |
USD 601.26B |
VX1:F | Vertex Pharmaceuticals Incorpo.. |
N/A |
USD 114.63B |
RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 106.63B |
CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 88.75B |
CSJ:F | CSL Limited |
N/A |
USD 88.09B |
0QF:F | Moderna Inc |
N/A |
USD 42.67B |
UNC:F | UCB SA |
N/A |
USD 26.08B |
UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 26.00B |
1AE:F | Argen-X |
N/A |
USD 24.59B |
1AEA:F | argenx SE |
N/A |
USD 24.49B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
FID | First Trust Intl Multi-As.. | 1.96 % | 0.69 % |
N/A |
USD 0.08B |
WDIV:AU | SPDR S&P Global Dividend | 1.45 % | 0.00 % |
N/A |
USD 0.25B |
EWH | iShares MSCI Hong Kong ET.. | 0.00 % | 0.48 % |
N/A |
USD 0.49B |
FGD | First Trust Dow Jones Glo.. | 0.00 % | 0.58 % |
N/A |
USD 0.53B |
WDIV | SPDR® S&P Global Dividen.. | 0.00 % | 0.40 % |
N/A |
USD 0.20B |
3110:HK | Global X Hang Seng High D.. | 0.00 % | 0.00 % |
N/A |
USD 2.16B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -57.51% | 12% | F | 5% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -57.51% | 12% | F | 4% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -66.70% | 18% | F | 7% | C- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -66.70% | 18% | F | 6% | D- | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -21.04% | 18% | F | 7% | C- | ||
Dividend Return | -21.04% | 18% | F | 7% | C- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 32.00% | 51% | F | 37% | F | ||
Risk Adjusted Return | -65.73% | 12% | F | 6% | D- | ||
Market Capitalization | 6.04B | 94% | A | 81% | B- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.